Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04715607
Previous Study | Return to List | Next Study

COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04715607
Recruitment Status : Recruiting
First Posted : January 20, 2021
Last Update Posted : March 10, 2021
Sponsor:
Collaborators:
Hvidovre University Hospital
Region Hovedstadens Apotek
Information provided by (Responsible Party):
Tobias Todsen, Rigshospitalet, Denmark

Brief Summary:
The aim of this study is to compare the SARS-CoV-2 detection rate using either a Saliva, oropharyngeal swabs or nasopharyngeal swab method for specimen collection.

Condition or disease Intervention/treatment Phase
SARS-CoV Infection Covid19 Coronavirus Diagnostic Test: Sequence of testing. Not Applicable

Detailed Description:

The reference test to evaluate patients with suspected respiratory infection caused by virus is a real-time reverse transcription-polymerase chain reaction (RT-PCR) from a nasopharyngeal swab (NPS). However, other specimen collection methods like oropharyngeal swabs (OPS) and a saliva specimen collection have also been accepted by the Centers for Disease Control and Prevention for SARS-CoV-2 testing during the current coronavirus disease 19 (COVID-19) pandemic. It is unclear how much the SARS-CoV-2 detection rate differs when using different sampling methods and the aim of this study is to compare the expected COVID-19 detection rate using saliva, oropharyngeal swabs or nasopharyngeal swab in a public setting.

We, therefore, aim to investigate the detection rate of SARS-CoV-2 in Saliva, oropharyngeal swab, and nasopharyngeal swab specimen samples collected in symptomatic and non-symptomatic individuals tested for COVID-19 in a public test center during the COVID-19 pandemic.

Individuals referred for outpatient COVID-19 testing center will be invited to participate in a prospective clinical study. They will have saliva, OPS, and NPS specimen collection performed at the same time and analyzed separately for SARS-CoV-2. The rate for SARS-CoV-2 detection in saliva, OPS, and NPS will be compared using a logistic regression mixed-effect analysis. A Sample Size Calculation estimated that a sample of 18,000 participants would be needed for the trial with 80% power at a significance level of 5%.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: All participants will have Saliva collected and recieve nasopharyngeal swabs and oropharyngeal swabs for SARS-COV2. To avoid systematic bias we plan to randomize the sequence of testing.
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Comparison of Detection Rate of SARS-CoV-2 in Saliva, Oropharyngeal and Nasopharyngeal Specimens in a Public COVID-19 Test Setting
Actual Study Start Date : January 22, 2021
Estimated Primary Completion Date : May 5, 2021
Estimated Study Completion Date : May 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Nasopharyngeal swab, oropharyngeal swab, and salvia collection

The participants will first be tested with nasopharyngeal swabs followed by oropharyngeal swab and saliva collection.

The collection material, virus transport medium and laboratory equipment for each method is the same in both arms

Diagnostic Test: Sequence of testing.
The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.

Active Comparator: Oropharyngeal swab, salvia collection, and nasopharyngeal swab

The participants will first be tested with oropharyngeal swabs followed by saliva collection and nasopharyngeal swab.

The collection material, virus transport medium and laboratory equipment for each method is the same in both arms

Diagnostic Test: Sequence of testing.
The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.

Active Comparator: Salvia collection, nasopharyngeal swab, and oropharyngeal swab

The participants will first be tested with saliva collection followed by nasopharyngeal swab and oropharyngeal swabs.

The collection material, virus transport medium and laboratory equipment for each method is the same in both arms

Diagnostic Test: Sequence of testing.
The participants will be tested in the following sequences of sampling technique: (1) nasopharyngeal swab, oropharyngeal swab, and salvia collection OR (2) oropharyngeal swab, salvia collection, and nasopharyngeal swab OR (3) salvia collection, nasopharyngeal swab, and oropharyngeal swab. Only the sequence is different in the different arm, while the sampling technique for each method is the same in all arms.




Primary Outcome Measures :
  1. SARS-CoV-2 detection rates for oropharyngeal swabs (OPS) compared with nasopharyngeal swabs and saliva collection. [ Time Frame: 48 hours after testing ]
    Due to the high specificity of RT-PCR, we will define a participant with an RT-PCR positive result from either Saliva, OPS or NPS as having a COVID-19 infection. The combined Saliva/OPS/NPS result will therefore be used as the diagnostic reference standard to calculate the sensitivity for the Saliva, OPS and NPS tests.


Secondary Outcome Measures :
  1. SARS-CoV-2 RT-PCR cycle threshold (Ct) values [ Time Frame: 48 hours after testing ]
    Ct values are compared between testing methods

  2. OPS, NPS and saliva test discomfort and likelihood to get retested [ Time Frame: immediately after testing (10 minutes) ]
    Discomfort scores (1-10) and likelihood to get retested are compared between testing methods

  3. Ratio of mutations in SARS-CoV-2 [ Time Frame: 48 hours after testing ]
    Detection rate of any mutations in SARS-CoV-2



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 120 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • volunteers, who are attending the COVID-19 test facilities to obtain a RT-PCR test.
  • oral and written informed consent to participate before entering the study.

Exclusion Criteria:

  • Failure to understand and provide informed consent.
  • Neck breathers (tracheostomy/laryngectomy patients) or other nasopharyngeal or oropharyngeal anomalies that do not allow for sampling using swabs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04715607


Contacts
Layout table for location contacts
Contact: Tobias Todsen, MD, PhD 00 45 3545 6033 Tobias.todsen@regionh.dk

Locations
Layout table for location information
Denmark
Valby COVID-19 teststed Recruiting
Copenhagen, Valby, Denmark, 2500
Contact: Tobias Gredal         
Sponsors and Collaborators
Rigshospitalet, Denmark
Hvidovre University Hospital
Region Hovedstadens Apotek
Investigators
Layout table for investigator information
Principal Investigator: Tobias Todsen, MD, PhD Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet
Study Director: Nikolai Kirkby, MD, PhD Department of Clinical Microbiology, Rigshospitalet
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Tobias Todsen, MD, PhD, Assistant professor Tobias Todsen, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT04715607    
Other Study ID Numbers: 2021-01
First Posted: January 20, 2021    Key Record Dates
Last Update Posted: March 10, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Severe Acute Respiratory Syndrome
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases